查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735697

全球麻疹、腮腺炎和德国麻疹病毒疫苗市场规模（按患者类型、通路、区域覆盖范围和预测）

Global Measles, Mumps, And Rubella Virus Vaccine Market Size By Patient Type, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

麻疹、腮腺炎及德国德国麻疹病毒疫苗市场规模及预测

2024 年麻疹、腮腺炎和德国麻疹病毒疫苗市场规模为 8.1956 亿美元，预计到 2032 年将达到 11.1303 亿美元，预测期内（2026-2032 年）的复合年增长率为 3.90%。

推动全球麻疹、腮腺炎和德国德国麻疹病毒疫苗市场的因素

麻疹、腮腺炎和德国麻疹病毒疫苗市场的市场驱动因素可能受到多种因素的影响，包括：

  • 政府免疫计画：推动 MMR 疫苗需求的主要因素是各国政府对旨在遏制麻疹、腮腺炎和德国德国麻疹等感染疾病传播的免疫宣传活动的兴趣和资金不断增加。
  • 教育与宣传：随着人们越来越意识到疫苗接种的价值及其如何帮助预防某些疾病，需求可能会增加。非政府组织、政府机构和医疗保健专业人员在提高大众对麻疹、腮腺炎和德国麻疹 (MMR) 疫苗益处的认识方面发挥着至关重要的作用。
  • 疾病发生率上升：由于世界各地爆发流行性腮腺炎和德国麻疹，疫苗接种需求增加。人们也担心，由于某些地区的疫苗接种覆盖率下降，这些疾病可能会再次出现，这也刺激了市场扩张。
  • 技术进步：疫苗技术的持续研发，推动了更安全、更有效的麻腮风（MMR）疫苗的研发。市场扩张得益于技术创新，例如单剂即可预防多种疾病的联合疫苗的研发。
  • 全球化与旅行：全球旅行和全球化的增加导致了流行性腮腺炎、腮腺炎和德国德国麻疹等感染疾病的传播，因此对于旅行者和交通繁忙地区的居民来说，接种疫苗至关重要。
  • 公共卫生紧急情况：疫苗可预防的疾病爆发，例如疫情和疫情，更加重视免疫接种计划，并导致对 MMR 疫苗接种的需求增加。
  • 政府法规和法律：MMR 疫苗的需求受到政府关于上学和前往某些国家旅行所需接种疫苗的严格法律和规定的推动。
  • 投资医疗保健基础设施：投资医疗保健基础设施将改善免疫服务的可近性，并增加对 MMR 疫苗的需求，尤其是在新兴经济体。

限制全球麻疹、腮腺炎和德国德国麻疹病毒疫苗市场的因素

麻疹、腮腺炎和德国德国麻疹疫苗市场面临许多限制和挑战，包括：

  • 错误讯息和疫苗犹豫：由于错误讯息和对疫苗的有效性、安全性和可能的​​副作用的担忧，这可能导致疫苗接种率下降和 MMR 疫苗市场萎缩。
  • 供应链挑战：复杂的供应链和物流挑战可能会阻碍 MMR 疫苗的取得和接种，包括疫苗分发和储存所需的低温运输，尤其是在农村和资源贫乏地区。
  • 生产成本高：MMR 疫苗的可负担性和可用性可能会受到疫苗生产高成本（尤其是在中低收入国家）以及严格的监管限制和品管标准的限制。
  • 全球经济不确定性：景气衰退、货币波动和医疗支出预算限制可能会导致 MMR 疫苗需求下降，这将影响政府、医疗保健提供者和个人对疫苗的负担能力。
  • 疫苗研发障碍：新型或改良 MMR 疫苗的市场进入可能会受到许多障碍的限制，包括漫长的研发时间、监管障碍以及持续研究和创新的需要。
  • 竞争环境：疫苗製造商（包括老牌企业和新进业者）之间的竞争非常激烈，这可能导致定价压力和利润率下降，从而可能阻碍市场扩张和研发支出。
  • 法律与监管障碍：这些障碍包括专利挑战、智慧财产权、监管核准程序等，可能会阻碍新疫苗进入市场或延迟新免疫接种的推出，进而影响整个 MMR 疫苗市场的成长。
  • 伦理和文化因素：实现较高的流行性腮腺炎-德国德国麻疹疫苗接种覆盖率可能会受到伦理问题、文化观点、宗教对疫苗接种的反对等因素的阻碍。这些因素可能会影响疫苗的接受度和接种率，尤其是在某些地区和社区。

目录

第 1 章全球麻疹、腮腺炎和德国德国麻疹病毒疫苗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

4. 全球麻疹、腮腺炎和德国麻疹疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球麻疹-腮腺炎-德国德国麻疹疫苗市场（依患者类型）

  • 概述
  • 儿科患者
  • 成年患者

6. 全球麻疹、腮腺炎和德国麻疹病毒疫苗市场（依通路）

  • 概述
  • 医院药房
  • 药局
  • 零售药局
  • 疫苗接种中心

7. 全球麻疹-腮腺炎-德国德国麻疹疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球麻疹、腮腺炎和德国德国麻疹疫苗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

第十章 附录

  • 相关调查
简介目录
Product Code: 35927

Measles, Mumps, And Rubella Virus Vaccine Market Size And Forecast

Measles, Mumps, And Rubella Virus Vaccine Market size was valued at USD 819.56 Million in 2024 and is projected to reach USD 1113.03 Million by 2032, growing at a CAGR of 3.90 % during the forecast period 2026-2032.

Global Measles, Mumps, And Rubella Virus Vaccine Market Drivers

The market drivers for the Measles, Mumps, And Rubella Virus Vaccine Market can be influenced by various factors. These may include:

  • Government Immunisation Programmes: A major factor driving up demand for MMR vaccines is governments' increased attention to and funding of immunisation campaigns aimed at stopping the spread of infectious diseases including the measles, mumps, and rubella.
  • Growing Education and Awareness: As people become more aware of the value of immunisation and how it helps avoid certain diseases, demand will rise. One of the most important roles in raising public awareness of the advantages of the MMR vaccine is the work done by NGOs, government organisations, and healthcare professionals.
  • Increasing Disease Incidence: The need for vaccinations is being driven by measles, mumps, and rubella outbreaks in different parts of the world. Market expansion is also fueled by worries about these illnesses' potential to resurface as a result of falling vaccination rates in some areas.
  • Technological Advancements: Ongoing research and development in vaccine technology results in the creation of MMR vaccines that are safer and more effective. Market expansion is aided by innovations like the creation of combination vaccinations, which provide protection against several illnesses with a single dose.
  • Globalisation and Travel: As a result of increased worldwide travel and globalisation, infectious diseases such as measles, mumps, and rubella are spreading, making immunisation against these diseases essential for travellers and residents of high-travel regions.
  • Public Health Emergencies: When diseases that are vaccine-preventable, like pandemics or outbreaks, occur, the demand for MMR vaccinations rises as a result of the emphasis placed on immunisation programmes.
  • Government Mandates and Laws: The demand for MMR vaccines is driven by governments' strict laws and mandates pertaining to vaccination requirements for school enrollment or travel to specific countries.
  • Investments in Healthcare Infrastructure: Investing in healthcare infrastructure increases access to immunisation services, which in turn increases demand for MMR vaccines. This is particularly true in emerging economies.

Global Measles, Mumps, And Rubella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Measles, Mumps, And Rubella Virus Vaccine Market. These may include:

  • Misinformation and Vaccine Hesitation: One major obstacle is vaccine hesitation, which is stoked by false information and worries about the efficacy, safety, and possible side effects of vaccines. Lower vaccination rates and a decline in the market for MMR vaccinations may result from this.
  • Supply Chain Difficulties: Especially in rural or resource-poor locations, the availability and accessibility of MMR vaccines may be hampered by complicated supply chains and logistical difficulties, such as the need for cold chain conditions for vaccine distribution and storage.
  • High Manufacturing Costs: The price and accessibility of MMR vaccines may be restricted due to the high cost of manufacturing vaccines, especially in low- and middle-income countries, as well as strict regulatory regulations and quality control standards.
  • Global Economic Uncertainty: Decreases in demand for MMR vaccines can result from economic downturns, currency changes, and budgetary limits in healthcare spending that affect the affordability of vaccines for governments, healthcare providers, and individuals.
  • Obstacles in the Development of Vaccinations: The market availability of novel and enhanced MMR vaccinations may be restricted by obstacles in the form of lengthy development schedules, regulatory barriers, and the requirement for ongoing research and innovation.
  • Competitive Environment: High levels of rivalry among vaccine producers, including both long-standing firms and recent arrivals, can lead to pressure on prices and narrowed profit margins, which impedes market expansion and R&D spending.
  • Legal and Regulatory Barriers: These obstacles, which include patent battles, intellectual property rights, and regulatory approval procedures, can impede the entry of new vaccines into the market or postpone the launch of new vaccinations, which can have an impact on the MMR vaccine market's overall growth.
  • Ethical and Cultural Factors: Obtaining high vaccination coverage rates for measles, mumps, and rubella can be hampered by ethical concerns, cultural views, and religious objections to vaccination. These factors can especially affect vaccine acceptance and uptake in certain communities or areas.

Global Measles, Mumps, And Rubella Virus Vaccine Market Segmentation Analysis

The Global Measles, Mumps, And Rubella Virus Vaccine Market are Segmented on the Patient Type, Distribution Channel, and Geography.

Measles, Mumps, And Rubella Virus Vaccine Market, By Patient Type

  • Pediatric Patient
  • Adult Patient

Based on Patient Type, the market is segmented into Pediatric Patient and Adult Patient. Pediatric vaccines are given in two dosages. First at 15 years old months and the second is before the age of six. Pediatric vaccines are more viable than adult vaccines. The adult vaccines are just a solitary portion of vaccination. As per CDC, grown-ups brought into the world in 1957 or later who have not been immunized or have not had measles are suggested one portion of the measles vaccine. The pediatric vaccine portion is assessed to represent a significant portion of the worldwide Measles, Mumps, And Rubella Virus Vaccine Market.

Measles, Mumps, And Rubella Virus Vaccine Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Vaccination Center

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores, Vaccination Center, and Retail Pharmacies. Vaccination centers are the most trusted channel for vaccination after that people prefer hospital pharmacies for vaccinations.

Measles, Mumps, And Rubella Virus Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the global Measles, Mumps, And Rubella Virus Vaccine Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the main share in the Measles, Mumps, And Rubella Virus Vaccine Market. A key factor driving the development of the market in the area is far-reaching government drives for vaccination against viral sicknesses. The Asia Pacific is arising as a critical district in the Measles, Mumps, And Rubella Virus Vaccine Market. Rising mindfulness among people of low monetary layers in agricultural nations of the district is a key factor impelling the measles, mumps, and rubella antibody market in the area.

Key Players

  • The major players in the Measles, Mumps, And Rubella Virus Vaccine Market are:
  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co. Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

Key Developments

  • In August 2021, Researchers from South Africa started a clinical experiment to see if the MMR vaccine for children may shield front-line medical staff from the Covid-19 virus or lessen the severity of the disease for individuals who contract it. Scientists from the Universities of the Witwatersrand (UW) and Cape Town (UCT) in South Africa started the trials.
  • In August 2021, GSK applied for PRIORIX (Measles, Mumps, and Rubella Virus Vaccine, Live) to be used in active immunization against measles, mumps, and rubella (MMR) infection by submitting an application for a biologic license (BLA) with the US Food and Drug Administration (FDA).
  • Ace Matrix Analysis
  • The ace matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Measles, Mumps, And Rubella Virus Vaccine Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the global Measles, Mumps, And Rubella Virus Vaccine Market, gauge the attractiveness of a certain sector, and assess investment possibilities

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY PATIENT TYPE

  • 5.1 Overview
  • 5.2 Pediatric Patient
  • 5.3 Adult Patient

6 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Drug Stores
  • 6.4 Retail Pharmacies
  • 6.5 Vaccination Center

7 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East And Africa

8 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 MedImmune
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Johnson & Johnson Private Limited
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Merck & Co., Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Sanofi
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Serum Institute of India Pvt. Ltd
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Bavarian NordicAstellas Pharma India Private Limited
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 CSL Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Emergent BioSolutions Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 GlaxoSmithKline plc
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 JC Medical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research